Keyphrases
Myelodysplastic Syndrome
100%
Erythropoietin
43%
Multiple Myeloma
38%
Anemia
30%
RhEPO
29%
Low-risk Myelodysplastic Syndromes
27%
Erythropoiesis-stimulating Agents
21%
Israel
20%
Erythropoietin Therapy
18%
Lenalidomide
17%
Transfusion Requirements
15%
Acute Myeloid Leukemia
13%
Thrombocytopenia
12%
Placebo
12%
Chemotherapy
12%
Myeloma
11%
RBC Transfusion
10%
Azacitidine
10%
Heart Failure
10%
Globin Genes
9%
European LeukemiaNet
9%
Red Blood Cell Transfusion
9%
Hemoglobin Level
9%
Acute Leukemia
9%
Platelet Count
9%
High-risk Myelodysplastic Syndrome
9%
Erythroid
9%
Eltrombopag
8%
Multiple Myeloma Patients
8%
Chronic Myeloid Leukemia
8%
Dependent Patients
8%
Platelets
8%
Hemoglobin
8%
Leukemia
8%
Red Blood Cells
8%
Erythropoietin Receptor
8%
Myelodysplasia
8%
T Cells
7%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Thrombosis
7%
Health-related Quality of Life
7%
Blood Transfusion
7%
Anemia Treatment
7%
Transfusion Independence
7%
Secondary Myelodysplastic Syndrome
7%
Platelet Function
7%
Bone Loss
7%
Immune Response
6%
Quality of Life
6%
Cytopenia
6%
Pharmacology, Toxicology and Pharmaceutical Science
Myelodysplastic Syndrome
75%
Erythropoietin
41%
Anemia
30%
Multiple Myeloma
29%
Recombinant Erythropoietin
29%
Disease
27%
Antianemic Agent
17%
Placebo
16%
Lenalidomide
16%
Acute Myeloid Leukemia
14%
Azacitidine
12%
Infection
11%
Mouse
11%
Neoplasm
11%
Thrombocytopenia
10%
Malignant Neoplasm
9%
Chemotherapy
9%
Myeloma
8%
Eltrombopag
7%
Heart Failure
7%
Thrombosis
7%
Clinical Trial
5%
Stimulant
5%
Hematologic Disease
5%
Cyclophosphamide
5%
Adverse Event
5%
Granulocyte Colony Stimulating Factor
5%
Dexamethasone
5%
Medicine and Dentistry
Myelodysplastic Syndrome
96%
Multiple Myeloma
25%
Disease
25%
Myelodysplastic Syndrome
18%
Hematinic
17%
Lenalidomide
17%
Anemia
15%
Erythropoietin
15%
Quality of Life
14%
Placebo
12%
Acute Myeloid Leukemia
11%
Thrombocytopenia
11%
Erythrocyte
10%
Myeloma
10%
Infection
9%
Platelet
8%
Acute Leukemia
8%
Heart Failure
7%
Azacitidine
7%
Blood Transfusion
7%
Erythrocyte Transfusion
7%
Erythrocyte
7%
Overall Survival
6%
Thrombocyte Function
6%
Bleeding
6%
Cytopenia
6%
Progression Free Survival
6%
Eltrombopag
6%
Thrombocyte Aggregation
5%
Myeloproliferative Disorder
5%
Neoplasm
5%